OTC-BB:TBPMF

Tetra Bio-Pharma Appoints Chief Financial Officer

Retrieved on: 
Monday, May 30, 2022
Physician, CPA, MBA, Inflammation, Pain, Company, News, Patient, Multimedia, Insurance, View, Plasma protein binding, Legislation, TSX, Research, FDA, Financial Executives International, Biotechnology, TBP, Forward-looking statement, Board, Terminology, Safety, Board of directors, FRA, Growth, CFO, CEO, Management, Pharmaceutical industry, Tetra

OTTAWA, ON, May 30, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022.

Key Points: 
  • OTTAWA, ON, May 30, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022.
  • She has held executive positions in biotechnology companies developing investigational new drugs, which is the core activity of Tetra.
  • Leslie has all the skills needed to bring Tetra to its next phase of growth.
  • I look forward to working with Leslie through these difficult market conditions to build Tetra into a successful pharmaceutical company," said Dr. Chamberland, CEO.

Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

Retrieved on: 
Tuesday, May 10, 2022
Tetra, COO, Forward-looking statement, Pain, True north, Insurance, Absorption, Company, Safety, Physician, Legislation, CFO, Patient, Doctor of Philosophy, FRA, FDA, Inflammation, Arbutus Biopharma, CCO, View, Chronic pain, TSX, Plasma protein binding, Terminology, Technology, Research, News, TBP, Multimedia, Generic drug, Pharmaceutical industry, CBD

OTTAWA, ON, May 10, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.

Key Points: 
  • OTTAWA, ON, May 10, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.
  • Tetra's patented technology leads to better absorption and aqueous emulsification of the CBD molecule in a variety of products.
  • "True North is pleased to have entered into a licensing agreement with Panag Pharma Inc. to exclusively incorporate their molecular technology into product formulations distributed under the True North brand.
  • Panag's patented CBD encapsulation technology is expected to further differentiate True North's branded product offering in the highly competitive medical and recreational CBD product market.

Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA

Retrieved on: 
Thursday, March 17, 2022
Tetra, Insurance, CRO, Inhalation, Literature, Legislation, Time, Human, Morphine, Patient, TBP, News, Cancer pain, Plasma protein binding, Toxicology, CBD, FDA, Pain, Multimedia, Hydromorphone, Risk, Animal, Benocyclidine, Hepatotoxicity, Forward-looking statement, Safety, Brain, Oxycodone, Cannabidiol, THC, U.S. FDA, Company, DDU, Research, Cannabinoid, CEO, Inflammation, CGMP, View, Chronic pain, Physician, TSX, Type, Pain management, Terminology, Marketing, FRA, Generic drug, Pharmaceutical industry

The Type C meeting with the FDA provides guidance to strengthen QIXLEEF nonclinical and toxicological data package for marketing approval.

Key Points: 
  • The Type C meeting with the FDA provides guidance to strengthen QIXLEEF nonclinical and toxicological data package for marketing approval.
  • OTTAWA, ON, March 17, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for its inhaled cannabinoid-based product, QIXLEEF.
  • The interactions with regulators, like the FDA, are critical for both the Company and shareholders.
  • The FDA guidance will pave the way for marketing approval and allow the Company to elaborate cost-effective strategy as part of the drug development program.